Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

France's Sanofi Scans China And Korea For Partnerships And Acquisitions As Part Of Global R&D Transformation

This article was originally published in PharmAsia News

Executive Summary

BEIJING - As part of a radical redesign of its worldwide research and development model, France's Sanofi-Aventis is searching for potential biotechnology partners in China and South Korea, according to Marc Cluzel, who heads Sanofi's global R&D operations

You may also be interested in...



Sanofi Looks To Build Stronger Alliances To Fuel R&D In Korea

Marking the conclusion of a 2009 MOU, Sanofi signed a letter of intent with the Korean government to take R&D investments to a new level.

Sanofi-Aventis Asia Pacific R&D Head Frank Jiang Sees Progress And Promise In Research Alliances Across China

BEIJING - As the Paris-headquartered Sanofi-Aventis expands its matrix of research alliances across China, this virtual R&D web is beginning to churn out tangible signs of progress and promise, according to a high-ranking Sanofi scientist based in China

Sanofi-Aventis Asia Pacific R&D Head Frank Jiang Sees Progress And Promise In Research Alliances Across China

BEIJING - As the Paris-headquartered Sanofi-Aventis expands its matrix of research alliances across China, this virtual R&D web is beginning to churn out tangible signs of progress and promise, according to a high-ranking Sanofi scientist based in China

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel